64.60

0.00% +0.00

Alpine Immune Sciences Inc (ALPN)

Overview News Price History Option Chain Financials Why ALPN Down? Discussions Forecast Stock Split

Alpine Immune Sciences Inc stock is currently priced at $64.60, with a 24-hour trading volume of 2.81M. It has seen a +0.00% increased in the last 24 hours and a +64.75% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $64.62 pivot point. If it approaches the $64.54 support level, significant changes may occur.

Previous Close:

$64.60

Open:

$64.62

24h Volume:

2.81M

Market Cap:

$4.24B

Revenue:

$58.88M

Net Income/Loss:

$-32.18M

P/E Ratio:

-46.81

EPS:

-1.38

Net Cash Flow:

$-79.50M

1W Performance:

-0.03%

1M Performance:

+64.75%

6M Performance:

+338.86%

1Y Performance:

+812.43%

1D Range:

$64.58

$64.68

52W Range:

$6.71

$64.72

Alpine Immune Sciences Inc Stock (ALPN) Company Profile

Name

Alpine Immune Sciences Inc

Sector

Healthcare (1210)

Industry

Biotechnology (681)

Phone

206-788-4545

Address

201 Elliott Avenue West, Suite 230, Seattle, WA

Employee

Twitter

@AlpineImmuneSci

Next Earnings Date

2024-05-09

Latest SEC Filings

ALPN's Discussions on Twitter

Alpine Immune Sciences Inc Stock (ALPN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-18-23	Initiated	Berenberg	Buy
Oct-17-23	Initiated	Berenberg	Buy
Oct-05-23	Initiated	RBC Capital Mkts	Outperform
Jun-26-23	Resumed	Oppenheimer	Outperform
Jan-19-23	Initiated	Morgan Stanley	Overweight
Nov-21-22	Initiated	SVB Leerink	Outperform
Dec-21-20	Initiated	H.C. Wainwright	Buy
Aug-26-20	Initiated	Cowen	Outperform

View All

Alpine Immune Sciences Inc Stock (ALPN) Latest News

Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline

Zacks Investment Research

Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now

The Motley Fool

Wall Street Breakfast: The Week Ahead

Seeking Alpha

Alpine Immune Sciences Inc Stock (ALPN) Financials Data

Alpine Immune Sciences Inc (ALPN) Revenue 2024

ALPN reported a revenue (TTM) of $58.88 million for the quarter ending December 31, 2023, a +95.84% rise year-over-year.

Alpine Immune Sciences Inc (ALPN) Net Income 2024

ALPN net income (TTM) was -$32.18 million for the quarter ending December 31, 2023, a +44.28% increase year-over-year.

Alpine Immune Sciences Inc (ALPN) Cash Flow 2024

ALPN recorded a free cash flow (TTM) of -$79.50 million for the quarter ending December 31, 2023, a -80.00% decrease year-over-year.

Alpine Immune Sciences Inc (ALPN) Earnings per Share 2024

ALPN earnings per share (TTM) was -$0.64 for the quarter ending December 31, 2023, a +61.90% growth year-over-year.

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.